JUL 7, 2016
Breast Cancer Blood Test Now Accessible Under Health Benefits for Millions of Women in the U.S.
Provista Diagnostics Announces 13 Signed Agreements with Third Party Administrator Networks
New York, NY – July 7, 2016 – Provista Diagnostics, a private company developing and commercializing protein-based diagnostic, prognostic and monitoring tests for cancers affecting women, today announced the signing of 13 agreements with Third Party Administrator (TPA) Networks for coverage of Videssa® Breast.
JUNE 2, 2016
Provista Diagnostics Announces Positive Trial Results Assessing the Use of Videssa® Breast to Detect Breast Cancer
Findings from Trial’s Second Cohort Replicate Prior Results
New York, NY – June 2, 2016 – Provista Diagnostics, a company developing and commercializing proteomic-based diagnostic, prognostic and monitoring tests for cancers affecting women, today announced positive results from Provista 002, a large, multi-center trial for its diagnostic test, Videssa® Breast. Representing over 500 patients, results from samples analyzed in the second cohort of the Provista 002 trial replicate findings from the first cohort, providing a strong clinical validation for the diagnostic assay.
Read MoreMAY 24, 2016
Provista Diagnostics to Present at The 2016 BIO International Convention
NEW YORK, NY – May 24, 2016 – Provista Diagnostics, Inc., today announces that David Reese, Ph.D., President and Chief Executive Officer, will deliver a corporate overview at the 2016 BIO International Convention,taking place June 6-9, 2016 at the Moscone Centerin San Francisco, California.
Read MoreAPR 6, 2016
Provista Diagnostics Announces New Chief Financial Officer and Expands Commercial Team Expertise
New York, NY – April 6, 2016 – Provista Diagnostics, Inc., a company developing and commercializing molecular diagnostic, prognostic and monitoring tests for cancers affecting women, has promoted Uriel Kusiatin, MBA to Chief Financial Officer and Kelly Gordon, PhD, MB (ASCP CM), to Vice President of Research and Development. Additionally, the company has filled senior positions on the rapidly expanding commercial team, with Doug Bradley, MBA joining as Vice President of Global Marketing, and Wendy Ross Morray joining as Senior Director of Reimbursement.
Read MoreMAR 21, 2016
Provista Diagnostics Closes $5.25 Million Financing
New York, NY – March 21, 2016 – Provista Diagnostics, Inc., a company developing and commercializing proteomic-based diagnostic, prognostic and monitoring tests for cancers affecting women, today announced the closing of an additional $5.25 million in preferred funding. This funding is comprised of capital gained from existing investors exercising warrants from a previous financing. The proceeds will be used for continued commercial development, prospective clinical trials, key management hires and general corporate purposes.
Read MoreMAR 16, 2016
Provista President and CEO David E. Reese Ph.D. Presents Company Overview and Videssa® Breast at Sachs Associates European Life Science CEO Forum & Exhibition
Presentation Spotlights Provista’s Blood-Based Diagnostic for Breast Cancer
New York, NY – March 16, 2016 – Provista President and CEO David E. Reese, PhD presented at the 9th Annual European Life Science CEO Forum and Exhibition in Zurich. Dr. Reese provided an overview of Provista and Videssa® Breast, the first blood test of its kind to provide early and accurate detection of breast cancer, scheduled to launch later this year.
Read MoreMAR 11, 2016
Provista Diagnostics’ Study First to Show that Age Should Be Considered When Developing Diagnostic Assays
Breast cancer blood test results are first to demonstrate age-related differences in Tumor-Associated Autoantibodies (TAAbs); data presented at Miami Breast Cancer Conference
New York, NY – March 11, 2016 – Provista Diagnostics, Inc., a company developing and commercializing proteomic-based diagnostic, prognostic and monitoring tests for cancers affecting women, today announced results of a study showing that age should be considered when developing diagnostic assays.
FEB 08, 2016
Provista Diagnostics to Present at The 18th Annual BIO CEO & Investor Conference
New York, NY – February 8, 2016 – Provista Diagnostics, Inc., today announces that David Reese, PhD, President and Chief Executive Officer, will deliver a corporate overview at the 18th Annual BIO CEO & Investor Conference taking place February 8-9, 2016 at The Waldorf Astoria in New York, NY.
Read MoreDEC 1, 2015
Provista Diagnostics Announces Pivotal Clinical Results for Videssa® Breast – A Simple Blood Test for Early and Accurate Breast Cancer Detection
Data to be Presented at the 101st Scientific Assembly & Annual Meeting of the Radiological Society of North America
New York, NY – December 1, 2015 – Provista Diagnostics, Inc. today announced that Ana Lourenco, M.D. of Rhode Island Medical Imaging will present data from their second prospective clinical study at the 101st Scientific Assembly & Annual Meeting of the Radiological Society of North America (RSNA) in Chicago, IL. Dr. Lourenco will be presenting “Proteomics at Work: Can a Protein-based Blood Assay Help Detect Breast Cancer in Women Aged 25-75 with BI-RADS® 3 or 4 Imaging Findings?” as part of the Breast Imaging (Practice Issues) Education Session.
NOV 18, 2015
Provista Diagnostics to Present at the 2015 Canaccord Genuity Medical Technology & Diagnostics Forum
New York, NY – November 18, 2015 – Provista Diagnostics, Inc., today announces that David Reese, PhD, President and Chief Executive Officer, will deliver a corporate overview at the upcoming Canaccord Genuity Medical Technology & Diagnostics Forum taking place November 19, 2015 at the Westin Grand Hotel in New York, NY.
Read More